TFMBOX

Pharmacodynamics The drug was assessed at and showed affinity for the serotonin 5-HT2A and 5-HT1A receptors, with Ki values of 340nM and 1,300nM, respectively. Its affinity for the serotonin 5-HT2A receptor was about 15-fold lower than that of DOB and DOI, whereas its affinity for the serotonin 5-HT1A receptor was the same as that of DOI and was about half that of DOB. TFMBOX also very weakly inhibited the reuptake of serotonin ( = 9,900nM), but did not affect dopamine or norepinephrine reuptake ( = >50,000–100,000nM). The drug fully substituted for LSD in rodent drug discrimination tests, albeit with about one-third of the potency of DOB and 2C-B. ==Chemistry==

Analogues Other "BOX" drugs that have been assessed include BOX (the cyclized analogue of 2C-H and DOH), BBOX (the cyclized analogue of 2C-B and DOB), and IBOX (the cyclized analogue of 2C-I and DOI). ==History==

TFMBOX was first described in the scientific literature by Nick Cozzi, a student of David E. Nichols, by 1994. ==See also==